EPO published patent application EP3570878A1 for an anti-HERV-K envelope antibody invented by Geneuro SA and U.S. Department of Health and Human Services researchers. The patent covers therapeutic antibodies classified under A61K 39/00, C07K 16/10, and C07K 16/112, with IPC classifications indicating applications for neurological (A61P 25/28) and neuromuscular conditions (A61P 21/04, A61P 21/00). The patent designates all major European states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).

This is a patent publication notice rather than a regulatory compliance requirement. Entities developing similar antibody therapeutics targeting HERV-K antigens or neurological/neuromuscular conditions should conduct freedom-to-operate analyses to assess potential infringement risks. IP counsel should review the claims scope and designated territory coverage for strategic considerations regarding licensing or design-around options.